Author

Sylvine Coutisson

Observed name: S. Coutisson

Institution: Médecins Sans Frontières

Observed institution: Médecins Sans Frontières

OpenAlex ID: A5057935409

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort

2022 · Catherine Hewison, Uzma Khan, et al. · Clinical Infectious Diseases · 56

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

2025 · Lorenzo Guglielmetti, Uzma Khan, et al. · The Lancet Respiratory Medicine · 33

One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India

2020 · Mrinalini Das, Alpa Dalal, et al. · Clinical Infectious Diseases · 29

Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs

2023 · Ismat Lotia Farrukh, Nathalie Lachenal, et al. · Clinical Infectious Diseases · 19

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

2023 · S. B. Patil, M. Tamirat, et al. · Trials · 13

Setting up pharmacovigilance based on available endTB Project data for bedaquiline

2020 · N. Lachenal, C. Hewison, et al. · The International Journal of Tuberculosis and Lung Disease · 11

Bedaquiline, Delamanid, Linezolid and Clofazimine for the Treatment of Rifampicin- and Fluoroquinolone-Resistant Tuberculosis (endTB-Q): A Phase 3, Open-Label, Multicentre, Randomised, Controlled, Stratified, Non-Inferiority Trial

2025 · Lorenzo Guglielmetti, Uzma Khan, et al. · SSRN Electronic Journal · 1

Works count: 7

Citation count: 162

H-index: 6

I10-index: 6